As a member of the Firm’s Corporate Practice Group, Paul focuses on general corporate representation, venture capital financings, mergers and acquisitions, and capital market transactions.
Paul advises start-up and late-stage companies through the entire corporate life-cycle, including pre-incorporation planning, seed, venture capital and growth financings, joint ventures and mergers and acquisitions. He also counsels venture capital funds in connection with venture and growth equity investments. Paul represents companies and investors in the technology and life sciences industries, including AI, biotechnology, cybersecurity, digital health, med tech, robotics and software.
Prior to joining Morse, Paul was a partner in the technology and life sciences group at Goodwin Procter LLP. Before Goodwin, Paul served as a senior corporate counsel at athenahealth, where he advised on corporate governance and securities matters, mergers and acquisitions, and the launch of its innovation and partnership program.
Representative Matters
Mergers and Acquisitions*
- Abide Therapeutics in its sale to Lundbeck
- Allurion Technologies in its business combination with Compute Health Acquisition Corp.
- Bend Financial in its sale to Webster Financial Corporation
- HealthEdge in its sale to Blackstone
- Helio Vision in its sale to Aldeyra Therapeutics
- iRobot Corporation in its acquisitions of Aeris Cleantec AG and Robopolis SAS
- Meilleur Technologies in its sale to Lantheus Holdings
- Mitralign in its sale to Edward Lifesciences Corporation
- Noetic Cyber in its sale to Rapid7
Venture Financings*
- Allurion Technologies in its preferred stock financings
- Arccos Golf in its $20 million Series C financing
- COTA in its equity and debt financings
- Health Data Analytics Institute in its $31 million Series C financing
- Labviva in its $20 million Series A financing and $25 million Series B financing
- Outcomes4Me in its $12 million Series A financing
- Tomorrow.io in its preferred stock financings, including its $87 million Series E financing
- Zus Health in its $34 million Series A financing
Public Offerings*
- Allurion Technologies in its $20 million follow-on offering
- BeiGene, Ltd. in its $200 million, $201 million and $800 million follow-on public offerings
- Underwriters in Flywire’s $256 million follow-on public offering
- Underwriters in Ibex Limited’s $90 million initial public offering
- Underwriters in Oscar Health’s $1.4 billion initial public offering
* Matters may have been handled prior to joining Morse.
Outside the Office
Paul enjoys golfing and spending summers with his wife and three sons down the Cape.
